StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX)

Investment analysts at StockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a note issued to investors on Sunday. The firm set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Trading Up 2.2 %

NYSE:BTX opened at $1.83 on Friday. Brooklyn ImmunoTherapeutics has a 1 year low of $0.17 and a 1 year high of $10.10. The firm has a market capitalization of $107.65 million, a PE ratio of -0.81 and a beta of 4.61. The firm’s fifty day simple moving average is $2.11 and its 200 day simple moving average is $1.79.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.